Brinder Kanda, MD
Interventional Cardiology · Richmond, VANPI 1306008974
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 44.6% of the total. 2025 is the largest year on record at $15,242, 7.4 times the $2,067 reported in 2019.
Across 371 payments — averaging $90.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Abbott$8K
- Edwards Lifesciences$7K
- Boston Scientific$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$323
- Cardiva Medical, Inc.$237
- plus $983 from 18 others
What the payments were for
- Consulting fees$1,0003%
- Speaking & faculty fees$2,1506%
- Travel & lodging$18,71456%
- Food & beverage$11,69435%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $14,974 |
| Abbott | 146 | $8,163 |
| Edwards Lifesciences | 84 | $6,745 |
| Boston Scientific | 40 | $2,156 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $323 |
| Cardiva Medical, Inc. | 8 | $237 |
| Materialise USA LLC | 2 | $234 |
| Abiomed | 6 | $135 |
| GE HealthCare | 1 | $111 |
| Novartis | 4 | $81 |
| Kestra Medical Technology Services, Inc. | 3 | $65 |
| W. L. Gore & Associates, Inc. | 1 | $44 |
| Penumbra, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Boehringer Ingelheim | 2 | $33 |
| Merck | 2 | $32 |
| Acist Medical Systems, Inc. | 1 | $29 |
| Heartflow, Inc. | 1 | $25 |
| Shockwave Medical, Inc | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Biosense Webster, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Cook Medical LLC | 1 | $16 |
| Biotronik Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$11,178
- MitraClip$3,299
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,387
- Micra$1,638
- CoreValve Evolut$1,122
- WATCHMAN Access System$1,000
- SAPIEN 3 Ultra RESILIA$367
- Watchman$318
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$269
- TRICLIP$260
- WATCHMAN FLX$144
- FFRangio$125
- MitraClip System$122
- SYMPLICITY G3$103
How this compares
$33,582 in reported general payments places this provider in the 85th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $39,339 |
| EntrestoSacubitril/Valsartan | 27 | $23,031 |
| XareltoRivaroxaban | 21 | $14,375 |
| BrilintaTicagrelor | 16 | $9,517 |
| Ranolazine ErRanolazine | 12 | $1,215 |
| ClopidogrelClopidogrel Bisulfate | 91 | $901 |
| Metoprolol Succinate | 48 | $755 |
| Atorvastatin Calcium | 56 | $493 |
| Carvedilol | 77 | $439 |
| Furosemide | 83 | $341 |
| Rosuvastatin Calcium | 27 | $315 |
| Losartan Potassium | 28 | $295 |
| Torsemide | 13 | $265 |
| Nitroglycerin | 15 | $179 |
| Lisinopril | 33 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $81 | $23,03127 claims |
| Johnson & JohnsonXarelto | $19 | $14,37521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Richmond
- Gansevoort DunningtonRichmond$440K
- Matthew ChungRichmond$75K
- Ashwani KumarRichmond$35K
- James GarnettRichmond$19K
- Barbara LawsonRichmond$17K
- John PosenauRichmond$11K
- Michael ArcareseRichmond$10K
- Sam DowRichmond$10K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.